J&J Settles Talc Cancer Claims for $5.5 Billion

Johnson and Johnson announced Monday it will pay an estimated 5.5 billion dollars to settle roughly 76,000 lawsuits claiming its talc-based baby powder and similar products caused ovarian cancer. The deal covers claims consolidated in federal court in New Jersey along with related state cases and marks the latest chapter in a legal fight stretching back more than a decade.

The company had already resolved most asbestos-related mesothelioma cases tied to the same products. Plaintiffs lawyers described the new agreement as a fair end to prolonged litigation. It still requires approval from at least 95 percent of the ovarian cancer claimants before it takes effect. Johnson and Johnson expects to pay 3 billion dollars in 2027 and additional amounts in 2028, with the total possibly rising higher depending on participation.

Company vice president of litigation Erik Haas called the claims meritless yet said the settlement brings needed closure. He noted the firm has won the vast majority of cases that reached trial and insisted the resolution lets Johnson and Johnson focus on developing medicines and devices. Plaintiffs attorney Chris Seeger, who represents about 2,500 clients and helped shape the deal, suggested the final payout could reach 7 billion dollars or more once all qualifying claims are tallied.

The lawsuits alleged Johnson and Johnson marketed talc products for feminine hygiene without adequate warnings despite studies dating back to the 1980s linking genital talc use to ovarian cancer. The company has long denied any connection and pointed to regulatory findings that its talc was asbestos-free. Earlier jury awards in some individual cases reached hundreds of millions before appeals or reductions.

This settlement arrives after Johnson and Johnson paid out billions in prior judgments and resolutions. Critics have long questioned whether large corporations can simply write checks to move past serious health allegations without fundamental changes in how they test or market consumer products. Everyday users who trusted the familiar baby powder brand now face the reality that a decade of court battles produced this massive payout rather than an earlier admission or product withdrawal.

The agreement does not include any admission of wrongdoing. It leaves open questions about how many additional claims might surface and whether the science behind the allegations will face renewed scrutiny in other venues. For the women and families involved, the money offers some compensation after years of legal wrangling, though it arrives long after the products were pulled from the market in much of the world. Johnson and Johnson maintains the cases lacked merit from the start, yet the scale of the settlement underscores the pressure these lawsuits placed on the company.